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We reviewed more than 3,000 pathology reports on prostate cancer-related surgical specimens and analyzed racial disparities
in histological and clinical features at the time of initial biopsy, diagnosis of prostate cancer, and prostatectomy, as well as
in characteristics of tumor evolution between African American and Caucasian patients. As compared to Caucasians, African
American patients had younger age, higher cancer detection rate, higher Gleason score of prostate cancer, and more bilateral
involvement of the prostate. African Americans also had larger prostates, greater volume of tumor, and more positive margins.
The diagnosis of HGPIN or ASAP in prostate biopsies and African American race conferred an increased risk of diagnosis of
prostate cancer. The interval between prior noncancerous biopsy and the subsequent biopsy with diagnosis of prostate cancer was
shorter in men with HGPIN, with ASAP, or of African American race.
1.Introduction
African American race along with age and family history are
well-established risk factors for prostate cancer [1]. A better
understanding of the racial disparities in prostate cancer
between African Americans and Caucasians is crucial to
elucidating the pathogenesis of this disease, developing
rational diagnostic and screening strategies, and facilitating
discovery of new interventions for prevention and treatment
of prostate cancer. That African Americans have higher inci-
dence and mortality rates than Caucasians is clear from epi-
demiological studies using nationwide databases such as the
SEER database maintained by the National Cancer Institute
[2]. Many studies have demonstrated that there was higher
detection rates of prostate cancer in biopsies from African
Americans compared to Caucasians [3–6], while other stud-
ies suggest that race might not be independently associated
with a positive biopsy in men suspected of having prostate
cancer[7–9].Ithasbeencommonlyacceptedthathigh-grade
prostatic intraepithelial neoplasia (HGPIN) is an important
histologicalprecursorofprostatecancersinceitwasprecisely
characterized by McNeal and Bostwick [10], and atypical
small acinar proliferation (ASAP) is a histological ﬁnding
associated with a high rate of current carcinoma not sampled
at the time of biopsy [11]. Both lesions are generally believed
to be important predictors for prostate cancer on rebiopsy
[12–14]. Racial diﬀerences in prevalence of these important
histologicalpatternshavebeendemonstratedinpriorstudies
[4, 15], but the signiﬁcance of such distinctions and appli-
cation of this knowledge are not agreed upon. For example,
the role of race in developing strategies for rebiopsy in men
with HGPIN is controversial [6, 16]. Thus, the inﬂuence
of these characteristic lesions on the evolution of prostate
cancer needs to be further studied.
There are many potential reasons for these discrepancies
between studies of racial diﬀerences in histological features
associated with prostate cancer, including lack of repro-
ducibility in the diagnosis of HGPIN or ASAP [13]. One of
the most important limitations in our understanding in this
area is that African Americans remain underrepresented in
most cancer studies [17–19]. There is a need for additional
studiesfromregionsandinstitutionswithpopulationswhich
include a substantial proportion of African Americans. The
population of Mississippi is comprised of a relatively stable2 Prostate Cancer
racial/ethnic mix, and most individuals in the state identify
themselves as either African American or Caucasian (∼98%)
with a nearly balanced proportion [20]. Less than 1% of peo-
ple from Mississippi were reported as more than one race in
census data [21]. Importantly, incidence and mortality rates
from prostate cancer in Mississippi rank among the nation’s
highest [22]. The current study will retrospectively analyze
the pathology reports and clinical data for African American
and Caucasian patients with prostatic diseases from the
Mississippi region. Wewillemphasizetheracialdisparities in
pathological and clinical features at the time of initial biopsy,
diagnosis of prostate cancer, and prostatectomy, as well as
in the characteristics of tumor evolution.
2.MaterialsandMethods
2.1. Patient Population, Data Collection, and Categorization.
All patients were registered at the University of Mississippi
Medical Center (UMMC), a state owned tertiary care hospi-
tal between 1989 and 2009. A large majority of the patients
were from Mississippi. Records of patients with surgical
specimens from the prostate or other sites with metastatic
prostate cancer were reviewed for this study. Of 2,403
patients, 1261 (52.48%) were African American, and 1019
(42.41%) were Caucasian, 9 (0.4%) were other races includ-
ing Asian, Hispanic, and American Indian. The remaining
114 (4.7%) were patients without racial/ethnic information
recorded.
Pathology reports for each surgical specimen were
reviewed. Patient medical history and laboratory data were
obtained from electronic databases at the UMMC. Most of
the pathologic diagnoses were made by one of the authors
(SB). Cases were categorized as benign, HGPIN, ASAP, pri-
mary prostate cancer, and metastatic prostate cancer. Spec-
imens with more than one diagnosis were included in only
one group by assigning them to the highest category present
indescendingorderfrommetastaticprostatecancer,primary
prostate cancer, ASAP and HGPIN to benign. Twenty-three
surgical specimens were excluded from the study: 6 with
benign diagnoses, including 3 adenomas, 1 leiomyoma and
2 papillomas, and 17 with malignant diagnoses, including
1 adenoid basal cell tumor, 1 adenocarcinoma unspeciﬁed,
2 sarcomas, 2 squamous cell carcinomas, 1 stromal and
epithelial tumor, and 10 transitional cell carcinomas. Racial
diﬀerences were analyzed only between African American
and Caucasian patients due to limited numbers from other
racial groups.
2.2. Prostatic Biopsy. Indications for an initial prostatic
biopsy included elevation of serum PSA (>4ng/mL),abnor-
mal digital rectum examination (DRE), and clinical mani-
festations of urinary outlet obstruction. Repeat biopsies were
mostly performed for patients who had previously negative
biopsy for prostate cancer in whom there was high clin-
ical suspicion for prostate cancer. Included in this study,
approximately 61% biopsies were standard sextant biopsies;
the other biopsy cases had a variable number of additional
biopsy cores. During the study period, a total of 2,248
prostatic biopsies were performed by multiple urologists.
All criteria and procedures and protocols were the same for
patients from African American and Caucasian populations.
2.3. Prostatectomy. In this study, a total of 442 prostates were
surgically removed. Among these, 361 (81.7%) cases were
radical retropubic prostatectomies, and 81 (18.3%) patients
underwent cystoprostatectomy. When the entire prostate (or
with urinary bladder in cystoprostatectomy) was removed,
it was immediately ﬁxed in formalin. The prostate, after the
removal of seminal vesicles, was weighed in grams at the
time of gross examination. A few prostates were not weighed
(mostly attached with diseased urinary bladder) and their
weights were estimated by three dimensional measurements
with the formula: weight (grams) = length (cm) × height
(cm) × width (cm) × 3.14/6 [23]. The entire prostate was
sectioned at 3mm thickness and processed and stained with
hematoxylin eosin routinely for pathology study. The per-
centage of tumor, the proportion of tissue area occupied by
tumor in the entire gland, was estimated by visual inspection
(mostly by SB). The tumor volume was calculated using the
formula: tumor volume (cm3) = %o ft u m o r× weight of
prostate (grams). The surgical and pathological procedures
were exactly the same for patients from African American
and Caucasian populations.
2.4. Parameters in the Evolution of Prostate Cancer. In order
tocomparethediﬀerencesintheevolutionofprostatecancer
between African American and Caucasians, the following
parameters were set for comparison: (1) detection rate and
features of prostate cancer in repeat biopsies, (2) laterality
of prostate pathology in initial biopsy, and (3) time interval
betweentwoconsecutiveprostaticbiopsies.Thetimeinterval
for evolution of prostate cancer was calculated from the
time of the latest negative biopsy to the time of the earliest
positive sampling in patients who were eventually diagnosed
as prostate cancer by repeat sampling.
2.5. Statistical Analysis. Chi-square test was used in com-
parison of rates or percentages; Wilcoxon-Mann-Whitney
test was used to compare medians; Student’s t-test was used
in comparison of means; exact binomial probabilities calcu-
lation was used in testing binomial distributions.
3. Results
A total of 3,315 pathology reports from 2,403 patients have
beenreviewed.Of3,315surgicalspecimensfromtheprostate
or other sites related to prostate tumors, 1480 (44.7%) were
diagnosed as benign changes including diagnoses of normal,
hyperplasia,andprostatitis;252(7.6%)asHGPIN;90(2.7%)
as ASAP; 1,435 as primary prostate cancer (43.7%); 35
(1.06%) as metastatic prostate cancer.
3.1. Racial Disparities in Detection Rate, Age, PSA Level, and
Tumor Grade at the Initial Biopsy. African Americans had
1,230 biopsies including 1,012 initial biopsies and 218 repeat
biopsies from 147 patients; Caucasian had 911 biopsiesProstate Cancer 3
Table 1: Diﬀerences in percentages of diagnoses at the ﬁrst biopsy between African American and Caucasian.
Diagnosis African American (n) Caucasian (n) P value
Benign (%) 37.2 (372) 48.4 (370) <0.0001a
Age (Year, mean ± SD) 60.9 ±8.9 (376) 63.5 ±9.2 (370) <0.0001
Serum PSA (ng/mL, median) 5.7 (170) 5.5 (146) >0.05
PIN (%) 9.1 (92) 9.9 (76) >0.05
Age (Year, mean ± SD) 61 ±7.7 (92) 62.4 ±7 (76) >0.05
Serum PSA (ng/mL, median) 6.7 (73) 5.5 (39) >0.05
ASAP (%) 3.3 (33) 2.9 (22) >0.05
Age (Year, mean ± SD) 60.5 ±9 (33) 62.4 ±7 (22) >0.05
Serum PSA (ng/mL, median) 5.1 (21) 5.8 (13) >0.05
Prostate cancer (%) 50.3 (509) 38.3 (293) <0.0001b
Age (Year, mean ± SD) 63.2 ±9 (509) 64.7 ±9.1 (291) 0.027
Serum PSA (ng/mL, median) 11.6 (346) 7 (162) <0.0001
Gleason’s score (n/mean ± SD) 6.9 ±1.5 (502) 6.3 ±1.5 (289) <0.0001
a:O R= 0.63, 95% CI: 0.52–0.76. b:O R= 1.63, 95% CI: 1.35–1.97.
Table 2: Diﬀerences in features at time of diagnosis of Pca between African Americans and Caucasians.
Features African American (n) Caucasian (n) P value
Prostate cancer detection rate (%) 49.2 (620) 40.8 (416) <0.0001a
Age (year, mean±SD) 63.1 ±9 (620) 64.7 ±8.8 (414) 0.0081
Gleason score (mean±SD) 6.9 ±1.6 (611) 6.3 ±1.6 (410) <0.0001
Serum PSA (ng/mL, median) 11.1 (404) 7 (213) <0.0001
Diagnosed by biopsy (%) 88.9 (551) 79.6 (331) <0.000b
First biopsy (%) 82.1 (509) 70.5 (293) <0.0001c
Repeated biopsies (%) 6.8 (42) 9.1 (38) >0.05
Diagnosed by TURP∗ (%) 6.5 (40) 9.6 (40) 0.074d
Diagnosed by prostatectomy (%) 4.7 (29) 10.8 (45) <0.0001e
∗TURP: Transurethral resection of prostate; a:O R= 1.4, 95% CI: 1.19–1.66; b:O R= 2.1, 95% CI: 1.45–2.89; c:O R= 1.93, 95% CI: 1.44–2.58; d:O R= 0.65,
95% CI: 0.41–1.02: e:O R= 0.41, 95% CI: 0.25–0.65.
including 765 initial biopsies, and 146 repeat biopsies from
121 patients. At the time of the initial biopsy, the age was sig-
niﬁcantly younger and the PSA level was signiﬁcantly higher
in African American than in Caucasian patients (mean age:
62 versus 63.8, P<0.0001, median PSA: 8ng/mL versus
5.8ng/mL, P<0.0001). As shown in Table 1, the detection
rate of prostate cancer on initial biopsy was substantially
h i g h e ri nA f r i c a nA m e r i c a np a t i e n t st h a ni nC a u c a s i a n
patients (50.3% versus 38.3%, P<0.0001), representing a
relative risk of 1.31. Conversely, benign diagnoses excluding
HGPIN, and ASAP on the initial biopsy were less common
in African Americans than Caucasians (37.2% versus 48.4%,
P = 0.001). There was no signiﬁcant diﬀerence in the detec-
tion rate of either HGPIN or ASAP between African Amer-
icans and Caucasians. The mean age at the time of initial
prostate biopsy was 1 to 2.5 years younger in African Amer-
ican patients regardless of the diagnosis. In patients with
diagnoses of benign, HGPIN and ASAP, there was no signif-
icant diﬀerence in serum PSA level between the two races.
The diﬀerence in PSA serum levels between patients with
a benign diagnosis and patients with a diagnosis of cancer
was much more dramatically increased in African American
men (5.7ng/mL versus 11.6ng/mL, a 103% diﬀerence) than
in Caucasian patients (5.5ng/mL versus 7ng/mL, a 27% dif-
ference).
3.2. Racial Disparities in Variables at the Time of Diagnosis of
Prostate Cancer. The racial diﬀerences in clinical and patho-
logic variables at the time of diagnosis for prostate cancer
are outlined in Table 2. African Americans not only had
signiﬁcantly higher detection rates of prostate cancer (49.2%
versus 40.8%, P<0.0001), but they were also younger (63.1
versus 64.7, P<0.0081), with higher Gleason scores (6.9
versus 6.3, P<0.0001), and with higher serum PSA levels
(11.1 versus 7, P<0.0001). Most prostate cancers were
diagnosed at the time of the initial prostate biopsy in both
races. This was especially true in African Americans, of 620
African American patients with prostate cancer, 509 (82.1%)
were diagnosed at the initial prostate biopsy, which was
signiﬁcantly higher than the proportion of Caucasian cancer
patients diagnosed at the time of the initial biopsy (293 out
of 416, 70.5%, P<0.0001).
3.3.RacialDisparitiesinPathologicFeaturesinRadicalProsta-
tectomy. Detailed pathologic features of prostatectomy and4 Prostate Cancer
Table 3: Diﬀerences in clinical and pathological features at prostatectomy between African Americans and Caucasians.
Features African American (n) Caucasian (n) P value
Total radical prostatectomy (%) 18.7 (236) 21.2 (216) >0.05
Cystoprostatectomy (%) 9.8 (23) 26.9 (58) <0.0001a
Incidental prostate cancer (%) 39.1 (9) 34.5 (20) >0.05
Prostate cancer in prostatectomy (%) 78.4 (185) 70.4 (152) >0.05
Age (year, mean ± SD) 58.7 ±6.8 (185) 61.5 ±7.4 (152) 0.0005
Gleason score (mean ± SD) 6.63 ±1.1 (184) 6.58 ±1.3 (149) >0.05
Positive surgical margin (%) 33.5 (62) 19.7 (30) 0.0005b
Extracapsular extension (%) 18.9 (35) 17.8 (27) >0.05
Seminal vesicle invasion (%) 9.7 (18) 8.6 (13) >0.05
Lymph node invasion (%) 3.2 (6) 1.3 (2) >0.05
Weight of prostate (grams, median) 46 (127) 45 (97) >0.05
% of prostate gland (median) 15 (114) 6.6 (94) 0.00506
Volume (cm3, median) 7.4 (114) 3 (93) 0.00185
a:O R = 0.31, 95% CI: 0.18–0.52; b:O R= 2.05, 95% CI: 1.243–3.38.
initial diagnostic reports were available for 185 African
American and 152 Caucasian patients. The racial diﬀerences
in pathologic features in radical prostatectomy and cysto-
prostatectomy specimens are summarized in Table 3.C a u -
casians had a higher proportion of cystoprostatectomy spec-
imens than African American patients (27.2% versus 9.8%,
P<0.0001). In cystoprostatectomy specimens, the rate of
incidental prostate cancer (primary purpose of surgically
removal of the prostate was not for prostate cancer) in cysto-
prostatectomy was 39.1% in African Americans and 34.5%
in Caucasians (no signiﬁcant diﬀerence). It is worth noting
that African American patients diagnosed with prostate can-
cer were almost 3 years younger than Caucasians at prosta-
tectomy (58.7 versus 61.5, P = 0.0005). African American
patients had a signiﬁcantly higher rate of positive resection
margins (33.5% versus 19.9%, P = 0.0005) than Caucasians.
Although the median weight of the prostate was almost
the same in the two races, African American patients had
a signiﬁcantly higher median percentage of tumors in the
gland (15% versus 6.6%, P = 0.014) or more than 2 times
of tumor volumes (7.4cm3 versus 3cm3, P = 0.012) as
compared to Caucasians. The diﬀerences in other pathologic
features, including Gleason score, were not signiﬁcant in the
prostatectomy specimens between the two races.
3.4. Racial Disparities in Progression and Evolution of Prostate
Cancer. In our study cohort, approximately 7–9% of the
patients diagnosed with prostate cancer were identiﬁed on
repeatprostatebiopsyprocedures(6.8%inAfricanAmerican
and9.1%inCaucasian).Thedetectionrateofprostatecancer
at the repeat biopsy varied with the diagnosis in previous
biopsies and races. As shown in Figure 1,b o t hH G P I Na n d
ASAP were associated with increased detection rates for
prostate cancer in subsequent biopsies. In African Amer-
icans, prostate cancer was detected by repeat sampling in
33% patients with ASAP diagnosed in previous biopsies; this
rate was signiﬁcantly higher than that in patients with PIN
(14.7%, P = 0.01, OR = 2.9, 95% CI: 1.4–6.2) or only
benign features (5.8%, P<0.0001, OR = 8.1, 95% CI:
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Figure 1: Comparison of prostate cancer detection rate in repeat
sampling between African American and Caucasian.
4.2–15.8) diagnosed in previous biopsies. The diﬀerence
in detection rate of prostate cancer between patients with
previous diagnosis of PIN and benign was also signiﬁcant
(14.7% versus 5.8%, P = 0.001, OR = 3.0, 95% CI:
1.6–4.8). In Caucasians, prostate cancer was detected by
repeat sampling in 20.6% of patients with PIN diagnosed in
previous biopsies; this rate was signiﬁcantly higher than that
in patients with ASAP (13.8%, P = 0.01, OR = 2.9, 95% CI:
1.4–6.2) or only benign features (5.1%, P<0.0001, OR =
4.8, 95% CI: 2.7–8.7) diagnosed in previous biopsies. There
was no statistical diﬀerence between the two races in the
detectionofprostatecancerbyrepeatsamplingfrompatients
with previous diagnoses of ASAP, PIN, and benign although
prostate cancer detected by repeat sampling in patients with
ASAP diagnosed in previous biopsy in African Americans
was 2.4 times higher than that in Caucasians (33.3% versus
13.8%, P = 0.067, OR = 3.1, 95% CI: 1–10).
In African American patients in which there was clinical
suspicious for prostate cancer, the time interval, which was
calculated from the time of noncancer at the previous biopsy
to the progression of prostate cancer at the subsequentProstate Cancer 5
Table 4: Diﬀerences in bilaterally distribution of HGPIN, ASAP, and prostate cancer diagnosed at the ﬁrst biopsy between African American
and Caucasian.
African American Caucasian P value
n/N n/N
HGPIN 41/90 (45.6%) 25/75 (33.3%) 0.004a
ASAP 7/30 (23.3%) 1/21 (4.8%) 0.119b
Prostate cancer 295/479 (61.5%) 97/274 (35.4%) <0.0001c
n = number of bilateral distribution; N = total cases with available information on pathology distribution; a:R a t i o= 2.51, 95% CI: 1.3–4.9; b: Odds Ratio =
6.08, 95% CI: 0.6–143.3; c: Odds ratio = 2.93, 95% CI: 2.1–4.
biopsy, was 7 months for those with previous diagnosis of
HGPIN or ASAP and 9 months for those with previous
diagnosis of benign. In Caucasian patients, that time interval
was 8 months for those with previous diagnosis of HGPIN
or ASAP and 22.5 months for those with previous diagnosis
of benign. These data suggest that prostate cancer might
progressmorerapidlyin AfricanAmericanswithpersistently
elevated PSA, especially those with previous diagnosis of
benign, as compared to Caucasians.
Information regarding laterality of prostate pathology
diagnosed at initial biopsy was available for 969 patients,
including 165 patients with HGPIN, 51 patients with ASAP,
and 753 patients with prostate cancer. African Americans
patients had higher percentages of bilateral distribution of
all HGPIN, ASAP, and prostate cancer than Caucasians. The
diﬀerences were signiﬁcant in HGPIN (P = 0.004) and in
prostate cancer (P<0.0001). Although African Americans
had a higher percentage of bilaterally distributed ASAP
than Caucasians (23.3% versus 4.8%) with an odds ratio of
6.08 (Table 4), the diﬀerence was not statistically signiﬁcant.
Theseresultssuggestthatprostatecancerwasmoreadvanced
in African Americans at the time of initial biopsy than in
Caucasians.
In 142 unilaterally distributed HGPIN and ASAP, it was
signiﬁcantly more commonly detected on the left side (88
out of 142, 62% in left half of prostate, with a Z-ratio of
+2.77,P = 0.0054).Thisleftpredominanceremainedsimilar
in both lesions of HGPIN and ASAP and in both races. The
signiﬁcance of this phenomenon is not determined but may
be due to the handedness of the physicians performing the
biopsies.
4. Discussion
This retrospective study demonstrates that, in this cohort
of African American and Caucasian men undergoing biopsy
or resection for prostate cancer, there are signiﬁcant racial
diﬀerences in clinical and pathologic parameters. African
Americans were younger at the time of initial biopsy and at
the time of cancer diagnosis. The detection rate for prostate
cancer was nearly 30% higher in African American men
undergoing an initial biopsy procedure than for Caucasian
men, and the cancers detected on initial biopsy procedure
were 70% more likely to be bilateral and with higher
Gleason scores in African Americans. Prostate cancers in
AfricanAmericanshadgreatervolumeandoccupiedahigher
percentage of the prostate gland than cancers in Caucasians,
and African Americans were more likely to have positive
surgicalresectionmarginsatprostatectomythanCaucasians.
If patients with positive surgical resection margins were
accounted into non-organ-conﬁned disease, African Amer-
icans had a signiﬁcantly higher rate of non-organ-conﬁned
diseases at the time of prostatecotomy for cancer as com-
paredtoCaucasians(non-organ-conﬁnedcaseswas43.4%in
African American 32.9% in Caucasian, P = 0.044, data not
shown in results). Of course, some positive surgical resection
margins might be technically produced by transection of
organ-conﬁned tumors.
Cancer detection at the time of the initial prostate biopsy
procedure was higher in both races in our study compared
to reported rates in the medical literatures [24, 25]. The Uni-
versity of Mississippi Medical Center is the only allopathic
medical school in Mississippi and is an important tertiary
referral center for medical care. Mississippi, in addition to
havingahighproportionofAfricanAmericancitizens,isalso
arelativelypoorstatewithlowerpercapitaincomeandfewer
physicianspercapitathanother states,whichmaycontribute
to lower rates of participation in health screening endeavors,
including PSA screening. These factors may contribute to
the higher rates of cancer detection on initial biopsy and
the higher levels of PSA at initial diagnosis, compared to
published data.
The focus of this review was to evaluate histological fea-
tures of prostate tissue samples including biopsies and resec-
tions to identify racial diﬀerences and to correlate the diﬀer-
ences with clinical factors associated with increased risk and
poor prognosis for prostate cancer in African Americans. We
were able to identify higher rates of prostate cancer precur-
sorsinAfricanAmericans andtoshowthatboth HGPINand
ASAP are important risk factors for subsequent diagnosis of
adenocarcinoma in both races. In fact, the risk of subsequent
cancer diagnosis for both HGPIN and ASAP was higher in
African American patients than in Caucasian patients. This
supports the concept that prostate cancer development in
African Americans is pathogenetically similar to tumorige-
nesis in Caucasian patients and is associated with the same
precursor lesions. Although African American patients were
younger at the time of initial prostate biopsy and at the
time of prostatectomy than Caucasian patients, their tumor
volumes were greater, probably accounting for the more
frequent positive margins, higher PSA levels, and higher fre-
quency of bilateral cancer detection on biopsies. All of these6 Prostate Cancer
ﬁndings indicate that signiﬁcant prostate cancer develops
at younger ages in African American men than Caucasians,
which could have important implications for the develop-
ment of evidence-based prostate cancer screening recom-
mendations. In our opinion, it is important to inform the
AfricanAmericanmeninourcommunitiesabouttherisksof
prostate cancer and encourage them to participate in appro-
priate screening programs. Whether African Americans
should begin the screening process at a younger age needs to
be further addressed. Health care providers need to be aware
of these clinical diﬀerences and increased risk factors for
African Americans.
Prostate cancer volumes in this review were estimates
based on visual evaluation of representative, but thorough
sampling and more accurate assessments of cancer volume
are available from other studies. In our study, the median
tumor volume in African Americans was approximately 2.5
times larger than that in Caucasians (7.4cm3 versus 3cm3);
however, the median weight of the entire prostate gland
was almost equal between the races (46 grams for African
American, 45 grams for Caucasian). The ratio of prostate
cancer volume between two races in this study was similar to
that reported by Sanchez-Ortiz et al. [26], in which African
Americans had 2.8 times larger prostate cancer volume than
Caucasians (2.5 times in our study). However, the mean
tumor volumes were much smaller (1.82cm3 for African
American, 0.72cm3 for Caucasian) in their study of patients
with nonpalpable T1 prostate cancer. Actually, the prostate
cancer volume for Caucasians in our study (3cm3)w a sc l o s e
to that (3.4cm3) reported by Moul et al. [27].
The reasons that African Americans develop prostate
cancer at younger ages with higher Gleason scores and
greater volumes than Caucasians remain unclear. Certainly,
delays in diagnosis could be an important factor in African
Americans having greater tumor volumes, but the fact that
African Americans in our study were younger at the time of
initial biopsy would suggest that biological factors could be
responsible for these disparities. The diﬀerences between the
races in androgen concentration, androgen sensitivity, diet,
and cultures could be some of the potential factors of the
racial disparities in prostate cancer. Perhaps African Amer-
icans have similar pathogenetic mechanisms in development
of prostate cancer to Caucasians, but they have a faster
growth rate and/or an earlier transformation to clinically
signiﬁcant prostate cancer as evidenced by Powell et al. [28].
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